EuBiologics

At a glance

EuBiologics filed 51 disclosures in the last 12 months, including 11 insider, 6 contract, 3 buyback and 1 5% holder. The most recent key filing was on Oct 26: Worth 7% of last year's revenue, over about 3 months.

Revenue for 2025 was ₩149B, up 55.4% on 2024. Operating margin was 40.7% against 35.7% a year earlier. Debt was 37% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩48.9B and operating profit of ₩10.8B.

The 2025 annual report lists 397 employees with an average tenure of 4.3 years and average pay of ₩60.8M, #1098 of 2,191 listed companies by average pay. Its 10 directors and auditors were paid ₩260M each on average. It paid no cash dividend for 2025. ㈜바이오노트 and related parties held 20.03% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 20.96% on Apr 7.

From the 2025 annual report

Staff: 397 (255 men, 142 women), of whom 19 on fixed-term contracts. Total pay for the year: ₩24.1B. Directors and auditors: 10, paid ₩2.6B in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜바이오노트 holds 19.92%; with 2 related parties the group holds 20.03% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Rankings: Operating margin #11 of 1,376 · Revenue growth #44 of 1,376

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

6 new supply contracts worth 53% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports